U.S. Markets close in 5 hrs 51 mins

COMPUGEN LTD. Registered Shares (CW9.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
15.00-1.20 (-7.41%)
As of 11:06AM CEST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close16.20
Open15.30
Bid15.30 x 350000
Ask15.90 x 350000
Day's Range15.00 - 15.30
52 Week Range3.40 - 16.70
Volume100
Avg. Volume914
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Our Take On Compugen's (NASDAQ:CGEN) CEO Salary
    Simply Wall St.

    Our Take On Compugen's (NASDAQ:CGEN) CEO Salary

    This article will reflect on the compensation paid to Anat Cohen-Dayag who has served as CEO of Compugen Ltd...

  • Compugen Starts Dosing In Early-Stage Combination Study For Solid Tumors
    SmarterAnalyst

    Compugen Starts Dosing In Early-Stage Combination Study For Solid Tumors

    Israel-based cancer immunotherapy firm Compugen announced that the first patient has been dosed in the Phase 1/2 study of COM701 with Bristol Myers Squibb’s (BMY) Opdivo and their investigational anti-TIGIT antibody-BMS-986207 for solid tumors.Compugen’s (CGEN) early-stage study is evaluating the safety, tolerability and preliminary antitumor activity of COM701 (the company’s first-in-class anti-PVRIG antibody) in combination with Bristol Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo (nivolumab) and BMS-986207.The study, which will initially enroll about 100 patients, will evaluate the simultaneous blockade of three immune checkpoint pathways, PVRIG, TIGIT and PD-1, and will accelerate the clinical evaluation of the's company DNAM axis hypothesis and biomarker strategy in patients with advanced solid tumors.Notably, the DNAM axis hypothesis suggests that PVRIG and TIGIT are two parallel and complementary inhibitory pathways and that blocking them may be required in certain tumor types to generate or enhance an anti-tumor immune response.Anat Cohen-Dayag, Compugen’s President and CEO stated, “The science we have elucidated behind this axis, combined with the preliminary antitumor activity observed in our Phase 1 COM701 study, suggest that our highly differentiated clinical path of targeting PVRIG simultaneously with TIGIT and PD-1 blockers has the potential to expand cancer immunotherapy treatment options to new patient populations.” (See CGEN stock analysis on TipRanks)On August 19, Leerink Partners analyst Daina Graybosch reaffirmed a Buy rating on Compugen with a price target of $19.00.Compugen stock has advanced by a stellar 159% year-to-date and the 12-month average price target of $19.33 implies upside potential of 25% ahead. The Street has a Strong Buy consensus for Compugen based on 3 recent Buy ratings.Related News: Mylan To Snap Up Aspen’s Thrombosis Unit For $757M As Street Is Bullish AstraZeneca’s Covid-19 Vaccine ‘Most Likely’ To Be Available In UK In Early 2021 Australia Signs $1.2B Covid-19 Vaccine Deals With AstraZeneca, CSL More recent articles from Smarter Analyst: * Slack Tanks 19% In After-Hours As 2Q Billings Miss Estimates * Lululemon Skids 6% As 3Q Profit Expected To Drop * Microsoft Joins Forces With Nutanix On Hybrid Cloud Solution * Lyft Rides Reach New High Since April; RBC 'Patiently Optimistic'

  • Compugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® and Anti-TIGIT Antibody
    PR Newswire

    Compugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® and Anti-TIGIT Antibody

    Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in the Phase 1/2 study evaluating the triple combination of COM701, Compugen's first-in-class anti-PVRIG antibody, with Bristol Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab), and their investigational anti-TIGIT antibody, BMS-986207.